Table 1 Comparing the clinical characteristics and laboratory measurements of the included CAPD patients with and without stroke
Characteristics | Overall | Case-control | p-value | |
|---|---|---|---|---|
Non-stroke | Stroke | |||
Patients (n) | 757 | 666 | 91 | Â |
Male (n, %) | 417 (55.1) | 368 (55.3) | 49 (53.8) | 0.9 |
Age (years, median [IQR]) | 49.0 [38.0, 60.0] | 48.0 [37.0, 58.0] | 62.0 [52.5, 68.5] | < 0.001 |
Serum albumin (g/l, median [IQR]) | 35.4 [31.8, 38.9] | 35.7 [32.0, 39.2] | 33.6 [31.2, 37.2] | 0.004 |
Hemoglobin (g/l, median [IQR]) | 81.1 (18.6) | 81.3 (18.6) | 80.0 (19.2) | 0.5 |
Serum calcium (mmol/l, median [IQR]) | 2.1 [1.9, 2.2] | 2.1 [1.9, 2.2] | 2.1 [1.9, 2.2] | 0.7 |
Serum phosphorus (mmol/l, median [IQR]) | 1.7 [1.5, 2.0] | 1.7 [1.5, 2.0] | 1.6 [1.3, 1.9] | 0.002 |
iPTH (pg/ml, median [IQR]) | 258.9 [141.3, 416.5] | 270.2 [153.9, 420.9] | 167.7 [87.7, 346.2] | 0.001 |
iPTH levels (n, %) |  |  |  | < 0.001 |
  ≤ 150 | 201 (26.8) | 158 (24.0) | 43 (47.3) |  |
 150–300 | 235 (31.3) | 215 (32.6) | 20 (22.0) |  |
 300–600 | 241 (32.1) | 223 (33.8) | 18 (19.8) |  |
  > 600 | 73 (9.7) | 63 (9.6) | 10 (11.0) |  |
SBP (mmHg, mean (SD)) | 140.8 (25.1) | 140.5 (24.9) | 143.6 (26.6) | 0.3 |
DBP (mmHg, mean (SD)) | 84.0 [73.0, 94.0] | 85.0 [74.0, 94.0] | 77.0 [66.0, 86.2] | < 0.001 |
Pulse pressure (mmHg, mean (SD)) | 57.4 (19.9) | 56.2 (19.1) | 67.4 (22.1) | < 0.001 |
Comorbid diseases | ||||
 Heart disease (n, %) | 208 (27.5) | 164 (24.6) | 44 (48.4) | < 0.001 |
 Atrial fibrillation (n, %) | 27 (3.6) | 21 (3.2) | 6 (6.6) | 0.2 |
 Hypertension (n, %) | 736 (97.2) | 645 (96.8) | 91 (100.0) | 0.2 |
 Diabetes (n, %) | 211 (27.9) | 162 (24.3) | 49 (53.8) | < 0.001 |
Agents | ||||
 Antiplatelet drugs (n, %) | 270 (35.7) | 208 (31.2) | 62 (68.1) | < 0.001 |
 Anticoagulants (n, %) | 15 (2.0) | 14 (2.1) | 1 (1.1) | 0.8 |
 RAAS blockades (n, %) | 600 (79.3) | 529 (79.4) | 71 (78.0) | 0.9 |
 CCBs (n, %) | 685 (90.5) | 597 (89.6) | 88 (96.7) | 0.05 |
 Calcium agents (n, %) | 604 (79.8) | 538 (80.8) | 66 (72.5) | 0.09 |
 Vitamin D (n, %) | 521 (68.8) | 472 (70.9) | 49 (53.8) | 0.002 |
 Statins (n, %) | 466 (61.6) | 399 (59.9) | 67 (73.6) | 0.02 |
Follow-up time (months, median [IQR]) | 54.7 (33.0) | 54.6 (32.7) | 55.5 (35.4) | 0.8 |
Composite endpoint (n, %) | 153 (20.2) | 117 (17.6) | 36 (39.6) | < 0.001 |